Area Nett AS Selects Hansen for Next-Generation Customer Information System
5.9.2024 12:00:00 CEST | Business Wire | Press release
Hansen Technologies Ltd (ASX:HSN), a leading global provider of software and services to the energy, water and communications industries, is pleased to announce that its Customer Information System, Hansen CIS, has been selected by Norwegian distribution service operator (DSO), Area Nett AS.
Area Nett AS is the grid owner in Northern Norway and ensures electricity supply to Gamvik, Lebesby, Karasjok, Måsøy, Nordkapp, Porsanger, and parts of Hammerfest. Hansen’s collaboration with Area Nett AS dates back to 2006. In 2016, however, Area Nett AS became a member of the purchasing collaboration with the Nettalliansen, which resulted in Area Nett AS temporarily switching to another KIS solution at the end of 2022. With this new agreement, Area Nett AS rejoins Hansen’s established customer base in Norway and other markets.
Area Nett AS will have access to the latest cloud-based functionality available, delivered as SaaS, and optimised for more efficient operational operations. The agreement also includes access to the new Hansen CIS user interface and the new self-service platform for end users.
Ingmar Hermansen, Head of Customer, Area Nett AS, commented: “Area Nett AS is pleased to select Hansen as our key technology partner for customer information systems, enabling us to adopt the latest functionalities tailored to DSO requirements.”
Baard Eilertsen, Executive Vice President for Energy & Utilities, EMEA Region at Hansen, commented: “We are proud of our longstanding relationship with Area Nett AS, and this agreement is significant for Hansen as it signals our intent to expand our market share in the electricity distributor domain in Norway. Delivering a host of new, advanced capabilities in an easy-to-implement SaaS model ensures that DSOs and retailers alike can seamlessly capitalise upon a modern approach to customer engagement.”
For further information about Hansen Technologies, please visit www.hansencx.com.
About Hansen
Hansen Technologies (ASX: HSN) is a leading global provider of software and services to the energy, water and communications industries. With its award-winning software portfolio, Hansen serves customers in over 80 countries, helping them to create, sell, and deliver new products and services, manage and analyse customer data, and control critical revenue management and customer support processes.
For more information, visit www.hansencx.com
About Area Nett AS
Area Nett AS is an electricity distributor in northern Norway, providing services to Gamvik, Lebesby, Karasjok, Måsøy, Nordkapp, Porsanger, and parts of Hammerfest. The company is part of the group Infranord SA, a merger of energy companies Luostejok, Nordkyn and Repvåg.
For more information, visit https://area.no/
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905082050/en/
Contacts
Adnan Bashir
Adnan Bashir
Global Lead, External Communications
Hansen Technologies
+1 647-204-0999
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom